A Phase 2/3 interventional study of High Calcium, Low Sodium (HCLS) Crystalloid Therapy and High Calcium, High Sodium (HCHS) Crystalloid Therapy in Cardiac Arrest and Pulseless Electrical Activity, sponsored by Carol Bernier. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-17.
Sponsored by Carol Bernier · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.
Among the 171 studies in Heart Arrest with a site in United States, this one is the 34th largest by planned enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2022, is one of 4 in phase 2/3, reaches primary completion later than 7 of the 44 other live ones, and was the 123rd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States, Brazil, Canada and 2 more countries
Ages 18+
University of Massachusetts, Worcester · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
Mayo Clinic · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 0 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 24 · Phase 3 12 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 342 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 72 across the 117 interventional studies, 157 across the 54 observational. Of the 114 that completed or were terminated, 50 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 171 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Carol Bernier as lead sponsor.
Carol Bernier has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
17 of the studies in Heart Arrest with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283850Phase 3Carol BernierSurviving PEA in Roanoke (SPEAR) Study | 2027-02 |
| NCT06109181Lexeo TherapeuticsGene Therapy for ACM Due to a PKP2 Pathogenic Variant | 2026-12 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT02664831MaineHealthImmunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS) | 2027-01 |
| NCT07656259Mayo ClinicCOMPARE-VENT Feasibility Pilot Study | 2027-02-28 |
Add all 17 to your calendar (.ics) → With an account.
Among the 171 studies in Heart Arrest with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Carilion Clinic and Virginia Tech Carilion School of Medicine, in conjunction with Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and Salem Fire-EMS, are studying the outcomes of patients experiencing Pulseless Electrical Activity (PEA). PEA refers to a type of cardiac arrest in which there is normal electrical activity in the heart however the heart still fails to contract to generate a pulse. Without heart contractions, which normally generates a pulse, the brain and other important organs fail to receive blood and oxygen. Unfortunately, the majority (97.3%) of patients that experience this rhythm do not survive and most don't even make it to the hospital. This study is trying to determine if the administration of a High Calcium, Low Sodium (HCLS) fluid in pre-hospital care will improve the chances of survival.
Generally, a sodium (salt) solution is provided to patients experiencing cardiac arrest. Studies have shown that lower sodium and higher calcium content may activate certain parts of the heart cells required to generate a pulse under PEA conditions.
This study is a double-blind, prospective, clinical trial. PEA patients will randomly receive either routine fluid therapy (salt solution) or a HCLS solution. While HCLS solution is not the standard fluid used by EMS providers responding to PEA, it is composed of FDA approved components and is occasionally used by EMS providers at their discretion in treating PEA. It is predicted that HCLS will either improve PEA survival or deliver similar outcomes as routine treatment. All patients will receive standard, high quality cardiac arrest and post-cardiac arrest care regardless of assigned treatment group.
Pursuant to a Waiver of Informed Consent, this investigation will automatically enroll all eligible PEA patients treated by Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and/or Salem Fire-EMS systems.
Once patients are enrolled, they will be de-facto randomized into one of two groups: control High Calcium-High Sodium (HCHS) or interventional High Calcium-Low Sodium (HCLS). Supervisors will have on their trucks, numbered-but-otherwise-blinded bags of half-normal saline or normal saline solution. The bags will be numbered, recorded and randomized by this study's investigators. Supervisors, when providing care, will universally administer 1g unblinded CaCl2 and then subsequently chose a crystalloid fluid set to use from their trucks randomly. The crystalloid will be administered as a wide open IV drip at a rate of at least 1000ml/hour, depending on gauge size, for as long as fluids are indicated for, likely resulting in a crystalloid dose of 0.5-2(L) liters. Each bag-set will have two bags of the same blinded unit to allow for treatment with up to (2L) 2 liters of fluid for a patient. Explicitly, all enrolled patients will be receiving calcium, it is only the crystalloid fluid (normal saline vs half-normal saline) that will differ. HCLS treatment was designed to be hyponatremic compared to normal saline (while both groups in this trial will be hypercalcemic compared to pure normal saline PEA therapy) in order to initiate low sodium inotropy.
The contents of the bag will be blinded to the supervisor. Neither the patient nor the supervisor will know which treatment was given thus ensuring double-blinding. Further, by randomly choosing a bag with no knowledge of its contents, the treatment will effectively be randomized. Both groups will otherwise receive current routine Advanced Cardiac Life Support and either standard post-arrest care or standard termination of care. Per Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and Salem Fire-EMS standard protocol, only patients who undergo ROSC on scene will be transported to a hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will receive a drip of blinded, intravenous, normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
Drug: High Calcium, High Sodium (HCHS) Crystalloid Therapy
Patients will receive a drip of blinded, intravenous, half-normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.
Drug: High Calcium, Low Sodium (HCLS) Crystalloid Therapy
Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
Also known as: (NDC) National Drug Code NDC 0264-7800-00 and NDC 0409-4928-11
Normal saline IV drip and 1g IV bolus Calcium Chloride.
Also known as: NDC NDC 0264-7802-00 and NDC 0409-4928-11
Event Survival
ROSC sustained until arrival at the emergency department and transfer of care to medical staff at the receiving hospital?
Time frame: Up to 1 hour
Any Return-Of-Spontaneous-Circulation (ROSC)
Did the patient achieve ROSC at any point during the resuscitation attempt?
Time frame: Through resuscitation efforts up to 1 hour after arrival to (ED) Emergency Department
Survival to hospital discharge
Did the patient survive to hospital discharge?
Time frame: Up to 30 days after admission to (ED) Emergency Department
Neurological outcome at hospital discharge
(CPC) Cerebral Performance Category Score and/or (mRS) modified Rankin Score at hospital discharge?
Time frame: Up to 30 days after admission to ED
Serum Electrolyte Values
All (BMP) Basic Metabolic Panel values will be collected, but there is a particular emphasis on serum sodium and calcium values.
Time frame: Up to 12 hour after admission to the (ED) Emergency Department
Plan to share: No — Unidentified data could be arranged to be shared with researchers who specifically request it, but this study is not currently (IRB) Institutional Review Board approved to do so.
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.